Phase 1b randomized controlled double blind trial to evaluate the safety and immunogenicity of GMZ2 malaria vaccine candidate in healthy Gabonese children aged 1 to 5 years

S. Bélard, S. Issifou, N. Ramadhani, P.G. Kremsner & B. Mordmüller
Background: Malaria is still a major health thread in Sub-Saharan Africa. An effective vaccine could be a sustainable control measure easy to integrate into health infrastructures such as the extended program on immunization. The malaria vaccine candidate GMZ2 is a recombinant fusion protein of conserved[for full text, please go to the a.m. URL]